Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction

Author： Limin Ma   Johnsen Niels   Hellstrom Wayne JG  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.19, Iss.11, 2010-11, pp. : 1427-1437

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction

By Kendirci Muammer   Bivalacqua Trinity J   Hellstrom Wayne JG  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 4, 2004-04 ,pp. : 923-932

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction

By  

Current Pharmaceutical Design, Vol. 12, Iss. 27, 2006-09 ,pp. : 3467-3484

Bentham Science Publishers

Access to resources Recommend Favorite

New phosphodiesterase inhibitors in the treatment of erectile dysfunction

By Anderson Paul CB   Gommersall Lyndon   Hayne Dickon   Arya Manit   Patel Hitendra RH  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 11, 2004-11 ,pp. : 2241-2249

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction

By Dorsey Philip   Keel Christopher   Klavens Meghan   Hellstrom Wayne JG  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1109-1122

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase 5 inhibitors and erectile dysfunction

By Sandner Peter   Svenstrup Niels   Tinel Hanna   Haning Helmut   Bischoff Erwin  

Expert Opinion on Therapeutic Patents, Vol. 18, Iss. 1, 2008-01 ,pp. : 21-33

Informa Healthcare

Access to resources Recommend Favorite